Dr. Sullivan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 813-745-4673- Is this information wrong?
Education & Training
- University of FloridaFellowship, Hematology and Medical Oncology, 1985 - 1988
- University of FloridaResidency, Internal Medicine, 1982 - 1985
- University of LouisvilleMS, Biochemistry, 1982
- University of Louisville School of MedicineClass of 1981
- University of LouisvilleBA, Biology, Summa Cum Laude, 1974
Certifications & Licensure
- FL State Medical License 1983 - 2022
- KY State Medical License 1988 - 2002
Awards, Honors, & Recognition
- Invited Speaker 150th Anniversary of Tianjin Medical University, 2011
- Visiting Professor Tianjin Medical University, Tianjin, China, 2010
- Margaret Fonda Award in Biochemistry University of Louisville, 2005
- Join now to see all
Clinical Trials
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Jun 02
- Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide Start of enrollment: 2000 Jun 01
- CP-609,754 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsMelphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.Joel G. Turner, Yan Cui, Alexis Bauer, Jana L. Dawson, Juan A Gomez, Jongphil Kim, Christopher L. Cubitt, Taiga Nishihori, William S. Dalton, Daniel M. Sullivan> ;Cancer Research. 2020 Oct 6
- 18 citationsPhase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami S. Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Ju...> ;Clinical Cancer Research. 2020 Jan 1
- 2 citationsLenalidomide‐based response‐adapted therapy for older adults without high risk myelomaRachid Baz, Syeda Mahrukh Hussnain Naqvi, Jae Hoon Lee, Jason Brayer, Nancy Hillgruber, Brooke L. Fridley, Kenneth H. Shain, Daniel M. Sullivan, Melissa Alsina> ;British Journal of Haematology. 2018 Dec 12
- Join now to see all
Journal Articles
- An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myelomaNishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M, Eur J Haematol, 1/20/2015
- Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRAC-mutant ovarian cancerKummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo P, Youn A, Chen AP, Ji J, Allen DE, Lih C-J, Mehaffey MG, Wal..., Clin Cancer Res, 1/1/2015
- Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancerKazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A, Mol Cancer Ther, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple MyelomaDaniel M Sullivan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Study of Sunitinib Malate (SM) in Subjects With Metastatic and/or Surgically Unresectable non-GIST Soft Tissue Sarcomas.Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV, ASCO Annual Meeting Proceedings, 1/1/2008
- Benefits (Survival) and Risks (30 Days Mortality) of Phase I Trials in Oncology.Djulbegovic B, Moreno C, Kumar A, Lush R, Munster PN, Daud AI, Garrett CR, Simon GR, Lancet JE, Sullivan DM, Phase I Program Physician and Nurses, ASCO Annual Meeting Proceedings, 1/1/2008
- Join now to see all
Lectures
- "XP01 and Nuclear Export Inhibitors in Multiple Myeloma and AML"1/24/2015
- "Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapy".Barcelona, Spain - 1/18/2014
- The Impact of Precision Oncology on Clinical Trials: Solving the Puzzle.The Westin O'Hare, Chicago - 1/9/2014
- Join now to see all
Other
- Efficacy of Topoisomerase I and II Inhibitors in Combination with Standard Chemotherapeutic Agents (Ara-C and Daunorubicin) in the Management of Acute Myeloid Leukemia...Saba HI, Sullivan DM, Loughran Jr TP, Moscinski LC, Sullivan PA, Morelli GA
1/1/2003 - "Fractionation, kinetic properties, and inhibition by L-methionine analogs of rat liver and kidney methionine adenosyltransferase isozymes"Sullivan DM, M.S. Thesis, University of Louisville
1/1/1982
Press Mentions
- Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019
- ORIEN Uses Big Data to Improve Care for High-Risk PatientsJune 12th, 2017
Hospital Affiliations
- Cleveland Clinic Indian River HospitalVero Beach, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: